N-of-1 Trials in Cancer Drug Development is a research paper published in Cancer Discovery (2023). On theSindex it has a DataRank of 0. It has been cited 44 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: R01CA242845
National Institutes of Health
Grant: R01CA273168
University of Texas MD Anderson Cancer Center
Grant: P30 CA016672
NCATS NIH HHS
Grant: UL1 TR000371
NCI NIH HHS
Grant: U01 CA180964
National Institutes of Health
Grant: 1R01CA273168-01
Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffold
National Institutes of Health
Grant: 5R01CA242845-04
Blocking tumor progression in therapy-responsive RET aberration-associated cancer
National Institutes of Health
Grant: 5U01CA180964-02
Informatics to enable routine personalized cancer therapy
National Institutes of Health
Grant: 4UL1TR000371-10
Center for Clinical and Translational Sciences (CCTS)
National Institutes of Health
Grant: 3P30CA016672-41S4
Cancer Center Support (CORE) Grant
FWCI
11.17
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals